Nektar Therapeutics (NKTR): Rumor News

NKTR – Takeover chatter being mentioned – potentially Bristol-Myers as a suitor.

Key Facts Surrounding This News Item

  • NKTR had a POWR Rating of B (Buy) coming into today.
  • NKTR was -2.25% below its 10-Day Moving Average coming into today.
  • NKTR was 1.43% above its 20-Day Moving Average coming into today.
  • NKTR was 14.88% above its 50-Day Moving Average coming into today.
  • NKTR was 52.65% above its 100-Day Moving Average coming into today.
  • NKTR was 122.82% above its 200-Day Moving Average coming into today.
  • NKTR had returned +41.58% year-to-date leading up to today’s news, versus a +0.31% return from the benchmark S&P 500 during the same period.

More Info About Nektar Therapeutics (NKTR)

Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. View our full NKTR ticker page with ratings, news, and more.

NKTR at a Glance

NKTR Current POWR Rating™
Overall POWR Rating™
NKTR Current Price $37.02 2.58%
More NKTR Ratings, Data, and News

NKTR Price Reaction

The day of this event (Mar. 2, 2018)
NKTR Closing Price$102.87 21.67%
NKTR Volume6,588,600
238.25% from avg
Leading up to this event
NKTR 1-mo return3.92%
After this event
NKTR 1-day return17.17%
NKTR 3-day return16.54%
NKTR 5-day return21.96%

NKTR Price Chart

The Top Stocks For 2019

More Nektar Therapeutics (NKTR) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NKTR News
Page generated in 0.9209 seconds.